There is an ongoing phase 3 randomized, double-blind and placebo-controlled trial (NCT03179631) aiming to characterize the long-term effects of Ataluren-mediated dystrophin restoration in DMD patients. Here, DMD is linked to Duchenne muscular dystrophy.